Nasdaqcompany
DevelopingMarket movement

Moderna Sets 52-Week High of $198.40 as Bernstein Reiterates $45 Target

Moderna touched a 52-week high of $198.40 on Friday, while Bernstein repeated a Market Perform rating and a $45 price target, per The Crypto Basic.

Why it matters

A $45 target against a $193.09 share price leaves a gap Bernstein did not close even as it warmed to the platform, so the analyst view and the market price point in opposite directions. With one source and an unfinished report of the Phase 3 detail, the significance for the wider crypto market is limited.

Key facts

The shares fell to $193.09 as of 10:07:21 a.m. ET, down 0.89% from Thursday's close of $194.82.

193.09 USDReported by The Crypto Basic

Moderna opened Friday at $195.23.

195.23 USDReported by The Crypto Basic

Bernstein reiterated its Market Perform rating and maintained a $45 price target.

45 USDReported by The Crypto Basic

At $193.09, the $45 Bernstein target sits about 76.7% below the share price.

76.7 %Reported by The Crypto Basic

Bernstein analyst Courtney Breen said the firm's third annual healthcare forum pointed to Intismeran as the clearest validation yet of Moderna's mRNA therapeutics platform.

Reported by The Crypto Basic

Bernstein said the next major question is whether that validation extends to additional indications and clinical settings.

Reported by The Crypto Basic

Moderna and Merck said the Phase 3 INTerpath-001 study of intismeran autogene in completely resected Stage IIB-IV melanoma met the benchmarks described, as The Crypto Basic reported without the full detail.

Reported by The Crypto Basic

What happened

Moderna shares reached $198.40 on Friday for a new 52-week high, then retreated to $193.09 as of 10:07:21 a.m. ET, leaving the stock down 0.89% from Thursday's close of $194.82, The Crypto Basic reported citing Yahoo Finance. The report said Moderna opened at $195.23. Bernstein, in the same report, reiterated its Market Perform rating and kept a $45 price target, about 76.7% below the $193.09 market price. Bernstein analyst Courtney Breen said takeaways from the firm's third annual healthcare forum pointed to Intismeran as the clearest validation yet of Moderna's mRNA therapeutics platform, and the question the firm flagged was whether that validation extends to further indications and clinical settings. That view follows an August Phase 3 readout of intismeran autogene, an individualized mRNA neoantigen therapy Moderna develops with Merck; The Crypto Basic reported that the Phase 3 INTerpath-001 study in patients with completely resected Stage IIB-IV melanoma met its stated benchmarks, though the report was cut off before the specifics. The Crypto Basic is the only outlet in this set covering the story, so the price figures and Bernstein's position rest on a single report.

How the story developed

  1. First report

    First report by The Crypto Basic

    Moderna Hits Fresh 52-Week High as Bernstein Validates mRNA Platform but Keeps $45 Target

    The Crypto Basic

  2. Update

    Moderna sets new 52-week high

    Shares touched $198.40 before retreating to $193.09, down 0.89% from the prior close of $194.82.

    The Crypto Basic

  3. Update

    Bernstein keeps Market Perform and $45 target

    The rating and price target were reiterated even as the firm's language on the mRNA platform strengthened.

    The Crypto Basic

  4. Update

    Bernstein healthcare forum takeaways

    Courtney Breen described Intismeran as the clearest validation yet of the mRNA therapeutics platform.

    The Crypto Basic

  5. Update

    August Phase 3 readout for intismeran autogene

    The INTerpath-001 study in completely resected Stage IIB-IV melanoma met the benchmarks Moderna and Merck described.

    The Crypto Basic

Affected entities

Original sources

PublisherReportRolePublished
The Crypto Basic
Crypto media
Moderna Hits Fresh 52-Week High as Bernstein Validates mRNA Platform but Keeps $45 TargetOriginal